1,8-Dihydroxyanthraquinone - CAS 117-10-2
Catalog number: 117-10-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
1,8-Dihydroxyanthraquinone, an anthraquinone derivative, could be widely used as antioxidant, dye intermediate and a raw material to synthesise sorts of products.
Danthron; dantron; Chrysazine; 1,8-dihydroxyanthracene-9,10-dione
-20ºC Freeze
1,8-Dihydroxyanthraquinone could be widely used as antioxidant, dye intermediate and a raw material to synthesise sorts of products.
Quality Standard:
Enterprise Standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Canonical SMILES:
1.Acute mouse and chronic dog toxicity studies of danthron, dioctyl sodium sulfosuccinate, poloxalkol and combinations.
Case MT;Smith JK;Nelson RA Drug Chem Toxicol. 1977-1978;1(1):89-101.
Because of an apparent typographic error in a US patent, there has been some confusion as to the acute oral toxicity of danthron and danthron in combination with dioctyl sodium sulfosuccinate (DSS). Acute oral toxicity studies in mice revealed LD50 values of greater than 7 gm/kg for danthron, 2.64 gm/kg for DSS and 3.42 gm/kg for danthron/DSS mixture (1:2 ratio). These results indicate that the lethality of these compounds is in the gm/kg range and not in the mg/kg range. A one year chronic toxicity study of danthron, dioctyl sodium sulfosuccinate, poloxalkol and combinations in dogs failed to reveal any toxic effects. In particular, there was no evidence of hepatotoxicity or of any changes in the myenteric plexuses in the chronically treated dogs.
2.Effects of long-term sennoside treatment on in vitro motility of rat colon.
Odenthal KP;Leng-Peschlow E;Voderholzer W;Müller-Lissner S Pharmacology. 1993 Oct;47 Suppl 1:146-54.
Colonic motility of rats chronically pretreated with either 10 or 40 mg sennosides/kg body weight daily, 30 mg sennosides/kg twice a week or 500 mg danthron/kg daily for 6 months has been evaluated in ex vivo preparations. Registration of colonic contractions 48 h after the last application of drugs or placebo revealed striking differences between the ascending, transverse and descending parts of the colon as well as between corresponding circularly or longitudinally orientated segments. Treatment did not influence motility in the various parts of the colon except some reduction in spontaneous motility in the descending colon. Response to electrical stimulation and acetylcholine was independent of treatment in most segments, but a decrease in maximal contraction was observed by the high daily sennoside dose and by danthron in the ascending colon and descending colon, respectively. Sensitivity to rhein, an active metabolite of sennosides, was similar in all groups. Thus, chronic treatment with anthranoids reveals no abnormal motility pattern but a residual pharmacological activity 48 h after the last administration of high doses.
3.Antitumour and immunosuppressive activity of hydroxyanthraquinones and their glucosides.
Hilgert I;Cudlín J;Steinerová N;Vanĕk Z Folia Biol (Praha). 1977;23(2):99-109.
Both isomeric monohydroxyanthraquinones (1a, b), three dihydroxyanthraquinones (alizarin 1c, chrysazin 1d, and anthraflavin 1e) and corresponding acetylated (2) and free (3) beta-D-glucosides were screened for antitumour and immunosuppressive activity. Furthermore, four O-acetyl and O-benzyl derivatives of alizarin (5a--d) were tested. Antitumour activity was judged by the inhibition of growth of syngeneic tumours in the treated recipients and immunosuppressive activity by the effect on tumour growth or on skin graft survival in pretreated allogeneic recipients; as standard of reference served the activity of certain cancerostatic or immunosuppressive drugs used in clinical practice. 1-Hydroxyanthraquinone (1a), alizarin (1c), chrysazin (1d), acetylated glucoside of 2-hydroxyanthraquinone (2b), 2-benzylalizarin (5c), and 1-acetyl-2-benzylalizarin (5d) were found to exhibit antitumour activity. Distinct immunosuppressive activity was detected in alizarin (1c), acetylated glucoside of 1-hydroxyanthraquinone (2a), acetylated glucoside of 2-hydroxyanthraquinone (2b), acetylated glucoside of chrysazin (2d), 2-acetylalizarin (5a), and 1-acetyl-2-benzylalizarin (5d). The group of hydroxyanthraquinone glucodises (3a--3d) exhibited neither antitumour nor immunosuppressive activity.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 27975-19-5 Isosteviol

(CAS: 27975-19-5)

A tetracyclic diterpenoid with a beyerane core has drawn attention because it can exhibit antihypertensive activity, reduce blood glucose, suppress cancer cells...

Droxicainide hydrochloride
(CAS: 149572-05-4)

The hydrochloride salt form of Droxicainide, a piperidine derivative, has been found to be an potential antiarrhythmic agent.

CAS 1246094-80-3 N-Cyclopropyl-N-methyl-2-aminotetraline hydrobromide

(CAS: 1246094-80-3)

N-Cyclopropyl-N-methyl-2-Aminotetraline hydrobromide is a MAO inhibitor.

CAS 1270083-24-3 Spadin

(CAS: 1270083-24-3)

Spadin is a potent and brain penetrating TREK-1 channel blocker (IC50 = 71 nM) displaying antidepressant activity. Spadin enhances dorsal raphe nucleus 5-HT neu...

CAS 258276-95-8 LEP(116-130)(mouse)

(CAS: 258276-95-8)

A synthetic leptin peptide fragment

(CAS: 317846-22-3)

JNJ-2408068 is a potent inhibitor of respiratory syncytial virus (RSV), exhibits potent antiviral activity with 50% effective concentrations (EC50s) of 1.4 and ...

CAS 1135417-31-0 Ac-IEPD-AFC

(CAS: 1135417-31-0)

Ac-IEPD-AFC is a peptide whose sequence is preferred recognition motif for the serine protease granzyme B. It is a fluorogenic substrate.

(CAS: 107257-28-3)

PK14105, a isoquinoline derivative, could bind to peripheral-type benzodiazepine sites so that it might be a potential radioligand to locate areas of neuronal d...

Chemical Structure

CAS 117-10-2 1,8-Dihydroxyanthraquinone

Quick Inquiry

Verification code

Featured Items